Pharmaceuticals & Medicals
Clinical finish to patent litigation threats over UK drug trials
Planned changes to the UK Patents Act are set to protect clinical trials for innovative drugs from infringement litigation, Nick Huber discovers...  »
Gates-backed humanitarian venture fends off domain payout demand
WIPO arbitrators extinguish attempt to wring half a million Euros from charitable UN fund dedicated to providing drugs to developing world...  »
Quality assurance for Australia
Dr Brett Lunn, managing partner of Australian IP specialists FB Rice, tells Jo Russell how his firm has created a high-calibre niche in the country's thriving IP market...  »
Asia IP focus – Part Two: Hong Kong
This bustling Chinese territory is a haven for foreign businesses – but it also attracts risks from mainland-linked shadow companies and the trade in bogus drugs, writes Anita Leung of Jones Day...  »
Asia IP focus – Part One: China
Branding challenges and burgeoning online piracy are just two of the hurdles that overseas companies aiming to do business in China will have to overcome, writes Li Chiang Ling of Jones Day...  »
Special series: Asia IP focus
NewLegal Review editor Matt Packer introduces four expert articles from international law firm Jones Day on the challenges of protecting IP in some of Asia’s most significant markets...  »
Australian law change puts patent attorneys in privileged class
In legal disputes in Australia, certain circumstances give rise to confidential documents being subject to production. But, in the context of IP law and patent attorney communications, those circumsta....  »
Change of pace
China is filing patents at an exceptional rate, but this creates difficulties as well as opportunities. Silvia Marchetti finds out how Yaochun Jiang, general manager and founding partner of Guangdong ....  »
Engine of Europe
Jo Tura uncovers Germany’s rich history of innovation, and explains how this has continued into the present day and helped Germany dominate the European market in patents and IP litigation....  »
EPO president defends organisation’s biotech procedures
Benoît Battistelli cites ‘stringent’ examination regime as evidence that patenting genetic inventions is not a simple formality...  »